Kanglong Chemitech Forecasts H1 2026 Revenue of 7.47–7.66 Billion Yuan, Net Profit Up 4–10% YoY

According to Kanglong Chemitech's announcement, the contract research and manufacturing organization (CRMO) provider forecasts H1 2026 revenue of 7.47–7.66 billion yuan, up 16–19% year-over-year, with net profit attributable to shareholders reaching 729–772 million yuan, up 4–10% YoY.

New contracts signed in the first half surged over 30% year-over-year, with lab services orders up over 20% and small-molecule CDMO service contracts up over 50%, driven by expanding strategic client partnerships and advancing project pipelines.